Literature DB >> 33537781

In vitro susceptibility testing for black grain eumycetoma causative agents.

Wendy W J van de Sande1.   

Abstract

Eumycetoma is a neglected tropical implantation mycosis characterized by large subcutaneous swellings. Inside the infected tissue, the causative agents are found in grains. The most common causative agents form black grains and are sterile upon isolation. In vitro susceptibility assays were developed for eumycetoma causative agents. They were based on the Clinical and Laboratory Standards Institute M38A protocol and modified to enable the use of hyphae as a starting inoculum. To ease endpoint reading, viability dyes such as resazurin or XTT have been used. So far the in vitro susceptibility assays developed have mainly been used to establish if causative agents are inhibited in growth by various antifungal agents, but not for clinical decision making. For drug discovery, the assay proved useful in determining which compounds were able to prevent hyphal growth. However, a clear correlation between in vitro inhibition in terms of the half maximal inhibitory concentration or 50% minimum inhibitory concentration (MIC50) and therapeutic efficacy assayed in a novel model system in terms of Galleria mellonella larval survival was not found. For clinical decision making, a range of MICs were found for each antifungal agent. However, no clinical breakpoints have been established for any of the causative agents. For itraconazole, the MIC50 of most causative agents was below the attainable serum levels, which might indicate that they are susceptible. However, before in vitro susceptibility can be used in clinical decision making for mycetoma, a correlation between MIC and clinical outcome needs to be made.
© The Author(s) 2021. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33537781      PMCID: PMC8046409          DOI: 10.1093/trstmh/traa184

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  66 in total

1.  Evaluation of a modified EUCAST fragmented-mycelium inoculum method for in vitro susceptibility testing of dermatophytes and the activity of novel antifungal agents.

Authors:  B Risslegger; C Lass-Flörl; G Blum; M Lackner
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Amphotericin B but not itraconazole is able to prevent grain formation in experimental Madurella mycetomatis mycetoma in mice.

Authors:  W W J van de Sande; W van Vianen; M ten Kate; A Fahal; I Bakker-Woudenberg
Journal:  Br J Dermatol       Date:  2015-10-23       Impact factor: 9.302

3.  In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals.

Authors:  Sarah Abdalla Ahmed; G Sybren de Hoog; David A Stevens; Ahmed H Fahal; Wendy W J van de Sande
Journal:  Med Mycol       Date:  2015-01-28       Impact factor: 4.076

4.  A rapid microplate method for the proliferation assay of fungi and the antifungal susceptibility testing using the colorimetric microbial viability assay.

Authors:  T Tsukatani; H Suenaga; M Shiga; K Matsumoto
Journal:  Lett Appl Microbiol       Date:  2014-05-05       Impact factor: 2.858

5.  New species of Madurella, causative agents of black-grain mycetoma.

Authors:  G Sybren de Hoog; Anne D van Diepeningen; El-Sheikh Mahgoub; Wendy W J van de Sande
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

6.  Antimycotic susceptibility testing of agents of black grain eumycetoma.

Authors:  P V Venugopal; T V Venugopal; E S Ramakrishna; S Ilavarasi
Journal:  J Med Vet Mycol       Date:  1993

7.  In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.

Authors:  Abdalla O A Ahmed; Wendy W J van de Sande; Wim van Vianen; Alex van Belkum; Ahmed H Fahal; Henri A Verbrugh; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

8.  Treatment of eumycetoma with ketoconazole.

Authors:  P V Venugopal; T V Venugopal
Journal:  Australas J Dermatol       Date:  1993       Impact factor: 2.875

Review 9.  Global burden of human mycetoma: a systematic review and meta-analysis.

Authors:  Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2013-11-07

10.  Madurella mycetomatis is highly susceptible to ravuconazole.

Authors:  Sarah Abdalla Ahmed; Wendy Kloezen; Frederick Duncanson; Ed E Zijlstra; G Sybren de Hoog; Ahmed H Fahal; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2014-06-19
View more
  2 in total

1.  Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.

Authors:  Wilson Lim; Bertrand Nyuykonge; Kimberly Eadie; Mickey Konings; Juli Smeets; Ahmed Fahal; Alexandro Bonifaz; Matthew Todd; Benjamin Perry; Kirandeep Samby; Jeremy Burrows; Annelies Verbon; Wendy van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2022-02-04

2.  Encapsulated eumycetoma caused by Biatriospora mackinnonii.

Authors:  Daniela Arteaga; Andrés Tirado-Sánchez; Denisse Vázquez-González; Luis-Miguel Moreno; Wendy van de Sande; Alexandro Bonifaz
Journal:  Med Mycol Case Rep       Date:  2022-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.